In older adults, treatment development ought to consider the barriers posed by cognitive

impairment and even develop treatments that target cognition as well as clinical symptoms. Research needs to consider and address the gaps raised in this review, most fundamentally our limitations in the diagnosis and measurement of anxiety disorders in older adults. The great public health importance of this research is highlighted by the graying of the world population, the high human and economic cost of anxiety disorders in all age groups, and the Inhibitors,research,lifescience,medical potential for existing and new treatments to reduce much of this burden. Acknowledgments This publication was supported by NIH grants R01 MH083648, R34 MH080151, and R34 MH086668. Notes Conflict of interest statement: Inhibitors,research,lifescience,medical Dr Lenze discloses that he has received research funding from Forest Laboratories, Johnson & Johnson, and Roche. He has been a consultant for Fox Learning Systems; Dr Wetherell discloses that she has received research funding from Forest Laboratories.
see more Traumatic Inhibitors,research,lifescience,medical brain injury (TBI) is an important, clinical problem in the United States and worldwide, but, after almost, 50 years of research, no safe, clinically effective treatment has been

found that can reduce mortality and morbidity and improve functional outcome. TBI has received more attention recently because of its high incidence in combat, casualties in Iraq and Afghanistan. US Department of Defense statistics indicate that as many as 30% of wounded soldiers seen at Walter Reed Army Hospital have suffered a TBI, a finding which has stimulated government interest in developing a treatment for this complex disorder. Both pediatric and geriatric TBIs are also on Inhibitors,research,lifescience,medical the rise as children of both sexes become more involved in contact, sports and as the elderly live longer, drive more, and become more susceptible to auto accidents and falls. A neuroprotective

treatment for stroke has also proven elusive. Well over 100 clinical trials for this incapacitating disease have yielded little substantive benefit Inhibitors,research,lifescience,medical for patients. Aside from tissue plasminogen activator (tPA), which can be given to only about 3% to 5% of stroke victims, and only in the first, 3 to 4 hours after stroke onset, nothing that shows any evidence of Cell press reduction of infarct size and neuroprotection is available for clinical use. Progesterone as a treatment for brain injury? Progesterone (PROG) is the bright exception to this grim picture. A search of PubMed using the keywords “progesterone, brain injury” yields over 200 publications from more than 25 independent, laboratories around the world using 22 different injury models demonstrating that PROG treatment can have beneficial effects leading to substantial and sustained improvements in cytological, morphological and functional outcomes.